Managing Director, PricewaterhouseCoopers
Chris Wasden is a Managing Director at PwC and the Global Healthcare Innovation Leader. Prior to PwC he led nine startups, that include corporate ventures, venture financed startups, incubators, and family owned businesses.
He is a named inventor on 20 issued patents. He has authored over 40 reports and papers on innovation that have outlined his philosophy and approach for successful innovation transformation. He helps organization apply mindful leadership to replace mindless management and senseless bureaucracy to increase the volume, velocity and value of their innovation efforts. His approach enables everyone in the organization to develop creative genius and to contribute to the innovation led growth of the enterprise.
Dr. Christopher Wasden has a doctorate in human and organizational learning from George Washington University in Washington, DC, an MBA from the UCLA Anderson School, and bachelors degrees in accounting and Asian studies from Brigham Young University in Provo, Utah.
1 blog from the author
Posted on 04.09.2013
Value creation capabilities based solely on R&D investment are not generating as much growth as they used to. According to PwC’s “Operating performance in the Medtech industry: Trends and imperatives” report, which studied the performance of 56 global medtech companies, the impact of R&D on revenue growth declined at an average annual rate of 10% and the return on invested capital declined at a rate of 2% between 2005 and 2011. The impact on growth is evident by revenue growth rates declining at a rate of approximately 12% per year.